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Abstract
Background: Tumor size is a critical variable in staging for renal cell carcinoma. Clinicians rely on radiological
estimates of pathological tumor size to guide patient counseling regarding prognosis, choice of treatment strategy
and entry into clinical trials. If there is a discrepancy between radiological and pathological measurements of renal
tumor size, this could have implications for clinical practice. Our study aimed to compare the radiological size of
solid renal tumors on computed tomography (CT) to the pathological size in an Australian population.
Methods: We identified 157 patients in the Westmead Renal Tumor Database, for whom data was available for
both radiological tumor size on CT and pathological tumor size. The paired Student’s t-test was used to compare
the mean radiological tumor size and the mean pathological tumor size. Statistical significance was defined as P <
0.05. We also identified all cases in which post-operative down-staging or up-staging occurred due to discrepancy
between radiological and pathological tumor sizes. Additionally, we examined the relationship between Fuhrman
grade and radiological tumor size and pathological T stage.
Results: Overall, the mean radiological tumor size on CT was 58.3 mm and the mean pathological size was 55.2
mm. On average, CT overestimated pathological size by 3.1 mm (P = 0.012). CT overestimated pathological tumor
size in 92 (58.6%) patients, underestimated in 44 (28.0%) patients and equaled pathological size in 21 (31.4%)
patients. Among the 122 patients with pT1 or pT2 tumors, there was a discrepancy between clinical and
pathological staging in 35 (29%) patients. Of these, 21 (17%) patients were down-staged post-operatively and 14
(11.5%) were up-staged. Fuhrman grade correlated positively with radiological tumor size (P = 0.039) and
pathological tumor stage (P = 0.003).
Conclusions: There was a statistically significant but small difference (3.1 mm) between mean radiological and
mean pathological tumor size, but this is of uncertain clinical significance. For some patients, the difference leads
to a discrepancy between clinical and pathological staging, which may have implications for pre-operative patient
counseling regarding prognosis and management.
Background
Tumor size is an important prognostic indicator for
renal cell carcinoma (RCC), and is thus a critical vari-
able in staging systems and a key factor when deciding
upon treatment strategy.
The 2009 TNM staging system for RCC stratifies
tumors limited to the kidney by their size alone (T1a
≤4 cm; T1b > 4 cm but ≤7 cm; T2a > 7 cm but ≤10 cm;
T2b > 10 cm) [1]. Available prognostic nomograms also
incorporate tumor size [2-5].
Renal tumor size also guides clinicians in recommending
radical nephrectomy (RN), partial nephrectomy (PN), abla-
tive techniques or active surveillance as the management
of choice. PN is the standard approach for T1a (≤4c m )
renal tumors, achieving equivalent oncological efficacy to
RN [6], while preserving renal function [7] and protecting
from non-cancer related mortality [8,9]. Several studies
support PN for all amenable T1b tumors (> 4 cm but
≤7 cm) [10-14]. The growing acceptance of PN as an
option for T1b tumors is reflected in current American
and European guidelines [15,16]. RN remains the therapy
of choice for T2 tumors (> 7 cm) [16,17]. Although recent
studies have demonstrated the feasibility of PN for
carefully selected patients with T2 tumors in experienced
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any medium, provided the original work is properly cited.centers [18,19], it is uncertain whether these results can be
extrapolated to all institutions. For high-risk surgical
candidates with small renal tumors, there is intermediate-
term data to support minimally invasive ablative techni-
ques such as cryoablation and radiofrequency ablation
(RFA) [20]. There is a relationship between tumor size
and local recurrence after ablation [20], and a tumor
size threshold of 3.5 cm has been proposed for such
techniques [17]. In patients with limited life expectancy,
active surveillance of small renal masses has been
advocated as a viable option, provided that tumor size is
less than 3 cm [21].
Most studies report patient outcomes following surgi-
cal intervention for RCC according to the pathological
size of the tumor, rather than the radiological size on
CT [2-5,22,23]. Indeed, the studies that have defined a
tumor size threshold for partial nephrectomy are all
based on pathological size [6,7,10-14].
Preoperatively, clinicians must rely on radiological
estimates of pathological tumor size to guide patient
counseling regarding prognosis and management. For
example, at institutions employing a size threshold for
PN, patients will be offered or denied PN based on
tumor size on CT. If there is a discrepancy between
radiological size on CT and pathological size, this may
have implications for clinical practice.
For patients undergoing ablative techniques, patholo-
gical tumor size cannot be determined. Therefore, stu-
dies report the outcome of ablative techniques
according to radiological tumor size [20]. If a discre-
pancy between radiological and pathological tumor size
exists, it may be difficult to meaningfully compare these
studies with the established evidence for nephrectomy,
which is reported according to pathological size.
A number of studies have examined the relationship
between CT size and pathological size of renal tumors
[24-36]. Most of these studies found that, on average,
CT overestimated pathological tumor size, although this
reached statistical significance in only three studies
[28,33,35]. Authors have disagreed on the clinical signifi-
cance of these findings. Only two of these studies com-
prehensively reported instances in which disagreement
between CT and pathological size led to discordance
between clinical and pathological stage [26,30]. To our
knowledge, there has been no such study performed on
an Australian population. A recent study has demon-
strated different trends in stage migration in an Austra-
lian RCC cohort compared with populations in the USA
[37]. Therefore, international findings are not necessarily
applicable to the Australian population and there is a
need for Australian data to be reported.
The aim of our study was to compare the radiological
size of RCC on CT to the pathological size in a contem-
porary Australian population. We also aimed to identify
patients who were up-staged or down-staged due to dis-
crepancy between CT and pathological size.
Methods
The Westmead Renal Tumor Database contains 547
patients whose tumors were removed by radical or par-
tial nephrectomy from 1994 to 2007. Data collection
and analysis was approved by the hospital ethics com-
mittee and complies with the Declaration of Helsinki.
We retrospectively reviewed the database and identified
157 patients for whom accurate data was available for
both radiological and pathological tumor size. Radiologi-
cal tumor size was defined as the largest transverse dia-
meter in the axial plane on CT scan, as measured by the
reporting radiologist. The CT protocol entailed pre-
contrast images and images in the arterial, corticomedul-
lary (venous) and excretory phases. Tumor size was
measured in the phase in which the tumor margins were
most obvious. Coronal and sagittal reconstruction images
were available, but the radiological tumor size was always
measured in the axial plane. Pathological tumor size was
defined as the largest transverse diameter, as measured
by the pathologist at examination of the surgical speci-
men prior to formalin fixation. There were 4 patients
with multifocal tumors. For these patients, we included
the data for their largest tumor in our analysis. According
to radiological size, tumors were grouped by 1 cm size
intervals and by clinically relevant size intervals (≤4c m ;
>4 cm but ≤7 cm; >7 cm but ≤10 cm; >10 cm).
We extracted demographic data for all patients from
the database, including age, sex, year of operation, type
of procedure (open or laparoscopic, radical or partial
nephrectomy), tumor histology (conventional, papillary,
chromophobe, other), Fuhrman grade, and clinical and
pathological tumor stage (according to 2009 TNM sta-
ging system).
The paired Student’s t-test was used to compare the
mean radiological tumor size and the mean pathological
tumor size. Statistical significance was defined as P <
0.05. Data analysis was performed using SPSS, version
15.0. We also compared mean radiological and mean
pathological size for tumors grouped by histological sub-
type, by type of procedure, by 1 cm size intervals and by
clinically relevant size intervals (≤4c m ;> 4c mb u t
≤7 cm; >7 cm but ≤10 cm; >10 cm).
For patients with pT1 and pT2 tumors, the radiologi-
cal and pathological tumor sizes were compared to
identify all cases of post-operative down-staging or
up-staging. We calculated the number and percentage
of patients for whom a difference between radiological
and pathological tumor sizes accounted for discrepancy
between clinical and pathological tumor stage.
We also examined the relationship between Fuhrman
grade and CT tumor size (grouped into clinically
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chi-square test. Of our cohort of 157 patients, 7 were
excluded from this analysis because they did not have a
Fuhrman grade recorded in the database. For the analy-
sis we grouped tumors into low-grade (Fuhrman 1 or 2)
and high-grade (Fuhrman 3 or 4).
Results
A total of 157 patients were identified, among whom
there were 51 (32.5%) women and 106 men (67.5%).
The mean (range) patient age was 63.3 (34-100) years.
The patients underwent surgery between 1998 and
2007. There were 18 (11.5%) patients treated with partial
nephrectomy (10 laparoscopic and 8 open procedures),
and 139 (88.5%) treated with radical nephrectomy (100
laparoscopic and 39 open). The histological tumor sub-
type was conventional in 126 (80.3%) patients, papillary
in 16 (10.2%), chromophobe in 11 (7.0%) and other in 4
(2.5%). The pathological tumor stage (according to the
2009 TNM staging system) was T1a in 58 (36.9%)
patients, T1b in 41 (26.1%), T2a in 18 (11.5%), T2b in 5
(3.2%), T3a in 30 (19.1%), T3b in 2 (1.3%), T3c in 2
(1.3%) and T4 in 1 (0.6%). Demographic data for our
study population is summarized in Table 1.
A scatter plot of pathological tumor size against radi-
ological tumor size is shown in Figure 1. Overall, the
mean radiological tumor size on CT was 58.3 mm (SD
29.2 mm) and the mean pathological size was 55.2 mm
(SD 30.5 mm). On average, CT overestimated pathologi-
cal size by 3.1 mm (95% CI: 0.7 to 5.5 mm, P =0 . 0 1 2 ) .
CT overestimated pathological tumor size in 92 (58.6%)
patients, underestimated in 44 (28.0%) patients and
equaled pathological size in 21 (31.4%) patients.
Among the 122 patients with pT1 or pT2 tumors, there
was a discrepancy between clinical and pathological sta-
ging in 35 (29%) patients. Of these, 21 (17%) patients
were down-staged post-operatively and 14 (11.5%) were
up-staged. This data is summarized in Table 2.
Table 3 shows the mean radiological and pathological
tumor sizes divided into 10 mm size intervals by radi-
ological size. Mean radiological size was greater than
mean pathological size for all size intervals, except for
the 50 - 59 mm and 70 - 79 mm categories. This only
reached statistical significance for tumors in the 80 - 89
mm category, for which mean radiological size was
13 mm larger than mean pathological size (95% CI: 1.26
to 24.74 mm, P = 0.034).
Table 4 shows the mean radiological and pathological
tumor sizes separated into clinically relevant size inter-
vals, corresponding to T1a (≤4 cm), T1b (>4 cm but
≤7 cm), T2a (>7 cm but ≤10 cm) and T2b (>10 cm)
stages. For all three groups, mean radiological size was
greater than mean pathological size but the difference
did not achieve statistical significance.
Table 5 shows the mean radiological and pathological
tumor sizes for the different histological sub-types. For
conventional RCC, CT overestimated pathological size
by an average of 3.8 mm (95% CI 1.25 to 6.39 mm, P =
0.004). There was no statistically significant difference
for the other histological subtypes.
Table 6 shows the mean radiological and pathological
tumor sizes stratified by type of procedure. For tumors
removed by radical nephrectomy, the mean radiological
size was 3.4 mm larger than the mean pathological size
(95% CI: 0.71 to 6.02 mm, P=0.013). There was no
Table 1 Demographic data for 157 patients
Feature N or Mean (%)
Age (years) 63.3 (34 - 100)
Sex
Male 51 (32.5)
Female 106 (67.5)
Year of Procedure
1998 2 (1.3)
1999 2 (1.3)
2000 6 (3.8)
2001 10 (6.4)
2002 18 (11.5)
2003 16 (10.2)
2004 10 (6.4)
2005 21 (13.4)
2006 34 (21.7)
2007 38 (24.2)
Type of Procedure
Laparoscopic PN† 10 (6.4)
Laparoscopic RN‡ 100 (63.7)
Open PN 8 (5.1)
Open RN 39 (24.8)
Histological subtype
Conventional 126 (80.3)
Papillary 16 (10.2)
Chromophobe 11 (7.0)
Other 4 (2.5)
Mixed 2
Neuroendocrine 1
Unclassified 1
Pathological T stage
pT1a 58 (36.9)
pT1b 41 (26.1)
pT2a 18 (11.5)
pT2b 5 (3.2)
pT3a 30 (19.1)
pT3b 2 (1.3)
pT3c 2 (1.3)
pT4 1 (0.6)
† PN - Partial nephrectomy.
‡ RN - Radical nephrectomy.
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removed by partial nephrectomy.
Table 7 shows radiological tumor size (grouped into
clinically relevant size intervals) distributed according to
Fuhrman grade. High-graded i s e a s e( F u h r m a n3o r4 )
was more common in larger tumors (≤4c mv s> 4c m
but ≤7c mv s> 7c m ;P =0 . 0 3 9 ) .T h ep r e v a l e n c eo f
high-grade disease was 24.5%, 31.1% and 50.0% for
tumors ≤4c m ,> 4c mb u t≤7 cm, >7 cm respectively.
Table 8 shows pathological T stage (grouped into T1a,
T1b and ≥ T2) distributed according to Fuhrman grade.
There was a statistically significant positive correlation
between Fuhrman grade and tumor stage (P = 0.003).
Discussion
Tumor size is an important prognostic indicator for
RCC. Outcome of nephrectomy has been studied
according to pathological tumor size. Pre-operatively, we
must rely upon CT estimates of pathological tumor size
to guide counseling regarding prognosis and choice of
treatment modality. Furthermore, ablative techniques for
renal tumors do not provide specimens for pathological
assessment of tumor size. When comparing emerging
ablative techniques to the benchmark of nephrectomy,
we are comparing data based on pathological tumor size
to data based on CT size. Therefore, it is important to
understand the relationship between radiological tumor
size and pathological tumor size, and to understand how
any difference between the two measurements affects
the accuracy of clinical staging.
Our study of a contemporary Australian cohort found
that overall CT overestimated pathological tumor size
by a statistically significant but small amount (3.1 mm).
This observation is consistent with the findings of pre-
vious studies. The findings of recent papers comparing
mean radiological and mean pathological renal tumors
sizes are summarized in Table 9. Kurta et al [28]
reported on the largest series (N =5 2 1 ) ,a n df o u n dt h a t
mean radiological tumor size was larger than mean
pathological tumor size by 1 mm. Similarly, CT was
found to overestimate pathological tumor size overall by
6.3 mm in a study by Herr [35], and by 10.0 mm in a
paper by Irani et al [33]. Schlomer et al [31] found no
statistically significant difference overall, but found that
CT overestimated pathological size for pT1a tumors by
3.9 mm and for lesions 40 to 50 mm by 8.7 mm. Simi-
larly, Lee et al [24] found a statistically significant over-
estimation of pathological tumor size by CT for tumors
in the 40 to 50 mm range only, by an average of 2 mm.
Choi et al [25] found that CT tumor size was on average
larger than pathological size for smaller tumors only
(<6 cm or T1). In several other series, mean radiological
tumor size was greater than mean pathological size, but
the difference did not reach statistical significance
[27,29,30,32,34,36]. Only one study reported an underes-
timation of pathological tumor size by CT overall,
and this achieved statistical significance for T1a tumors
only [26].
Analysis by histological subtype in our series showed a
statistically significant difference for conventional RCC
only, with CT overestimating pathological size by an
average of 3.8 mm. The small number of papillary (N =
18) and chromophobe (N = 11) tumors included in our
study meant we were unlikely to detect a statistically
significant difference. Several studies have shown that
CT size is greater than pathological size on average for
conventional RCC, and smaller than pathological size on
Figure 1 Scatter plot of pathological tumor size against
radiological tumor size. Please see attached image file.
Table 2 Discrepancy between clinical and pathological stage in 122 pT1 and pT2 tumors
Clinical stage (n) Pathological stage (n) Downstaged (n) Upstaged (n)
T1a 52 58 - 6 cT1a to pT1b
T1b 48 41 12 cT1b to pT1a 6 cT1b to pT2a
T2a 15 18 4 cT2a to pT1b
1 cT2a to pT1a
2 cT2a to pT2b
T2b 7 5 4 cT2b to pT2a -
Total 122 122 21 (17%) 14 (11.5%)
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found that CT overestimated pathological tumor size by
2.3 mm for conventional RCC and underestimated
pathological tumor size by 5.4 mm for papillary RCC.
Similarly, Lee et al [24] found that CT size was 1.4 mm
greater than pathological size on average for conven-
tional RCC, and 5.3 mm smaller for papillary RCC. In
contrast, Herr [34] found that pathological size was
overestimated on CT for all histological subtypes, and
that the overestimation was significantly greater for con-
ventional RCC compared to other subtypes (9.7 mm
versus 3.9 mm). Similarly, Choi et al [25] demonstrated
that mean radiological tumor size was larger than mean
pathological tumor size for all histological subtypes, but
there was no significant difference between groups.
The discrepancy between clinical and pathological
tumor size has been attributed to decreased tumor
vascularity after excision, leading to a diminished size
post-operatively [34]. This effect is probably more pro-
nounced for clear cell carcinomas because they typically
have a richer vascular network than other histological
subtypes. Yaycioglu et al [32] postulated that certain
radiological and pathological features might influence
the accuracy of tumor size measurement by CT. These
features included: concomitant pyelonephritis, presence
of hemorrhage or hematoma, cystic tumor or adjacent
cysts, dilatation of adjacent renal calyces and invasion of
the collecting system. The same study found that tumor
invasion of perinephric tissues impacted upon the accu-
racy of CT. For these tumors, CT more frequently
underestimated pathological size when compared to
tumors confined to the kidney. Ates et al [26] demon-
strated less accurate CT measurement of tumor size for
l o c a l l yi n v a s i v et u m o r s .I tm a yb em o r ed i f f i c u l tt o
delineate the radiographic margin of invasive tumors on
CT, leading to disagreement between radiological and
pathological tumor sizes. Ates et al [26] also found
more accurate measurement of tumors size on CT for
exophytic lesions. Herr [35] found that CT more closely
approximated pathological tumor size for upper pole
tumors, but other studies have failed to confirm this
finding [24,32,33]. Additionally, in our study the radiolo-
gical and pathological tumor sizes were not necessarily
measured in the same geometric plane and this could
contribute to the discrepancy between the two measure-
ments. The largest tumor diameter on CT was measured
in the axial plane, and this did not always correspond to
the plane in which the largest diameter was measured at
pathological exam. Formalin fixation is known to cause
tumor shrinkage [38], but in our series the pathological
specimens were examined prior to fixation.
Inaccurate CT estimation of pathological tumor size
led to discordance between clinical and pathological
stage in over one quarter of tumors limited to the
Table 3 Mean radiological and pathological tumor size (mm) divided into 10 mm size intervals by radiological size
CT size (mm) † N Mean CT size (SD) ‡ Mean pathological size (SD) Mean difference (95% CI) § P value
10 to 19 3 16.00 (2.65) 21.67 (7.64) 5.67 (-16.60 to 27.90) 0.388
20 to 29 17 23.24 (3.11) 23.18 (4.85) 0.59 (-1.99 to 2.10) 0.952
30 to 39 16 33.13 (3.07) 31.50 (10.56) 1.63 (-3.45 to 6.70) 0.506
40 to 49 32 42.41 (3.19) 39.19 (10.12) 3.22 (-0.42 to 6.85) 0.081
50 to 59 20 52.25 (3.14) 53.25 (2.40) -1.00 (-5.76 to 3.76) 0.665
60 to 69 22 61.77 (2.74) 56.55 (16.37) 5.23 (-1.93 to 12.39) 0.144
70 to 79 13 71.00 (1.96) 73.46 (10.68) -2.46 (-9.02 to 4.10) 0.430
80 to 89 9 82.44 (3.13) 69.44 (15.89) 13.00 (1.26 to 24.74) 0.034
90 to 99 6 91.50 (2.35) 80.00 (14.83) 11.50 (-2.24 to 25.24) 0.084
≥100 19 116.21 (22.29) 109.47 (36.09) 6.74 (-8.38 to 21.85) 0.361
† mm = millimetres.
‡ SD = standard deviation.
§ CI = confidence interval.
Table 4 Mean radiological and pathological tumor size (mm) divided into clinically relevant size intervals by
radiological size
CT size (mm) N Mean CT size (SD) Mean pathological size (SD) Mean difference (95% CI) P value
≤40 55 31.51 (8.17) 30.58 (10.59) 0.93 (-1.30 to 3.15) 0.407
> 40 but ≤70 65 56.94 (8.50) 55.14 (16.08) 1.80 (-1.43 to 5.03) 0.269
> 70 but ≤100 26 89.00 (9.26) 80.96 (29.05) 8.04 (-2.66 to 18.73) 0.134
> 100 11 128.00 (23.04) 117.73 (27.78) 10.27 (-2.17 to 22.71) 0.096
† SD = standard deviation.
‡ CI = confidence interval.
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patients were down-staged and 14 (11.5%) up-staged
post-operatively. There is limited published data on the
impact that disagreement between radiological and
pathological tumor sizes may have on staging discrepan-
cies. Kanofsky et al [30] reported on a series of 198
renal cell carcinomas and identified 21 patients for
whom disagreement between CT and pathological
tumor size led to discrepancy between clinical and
pathological tumor stage. Of these, 15 patients were
down-staged and 6 up-staged post-operatively. Ates et al
[26] found that differences between radiological and
pathological measurements led to staging discrepancies
in 19 of 86 patients, with 6 patients being down-staged
and 13 patients being up-staged post-operatively. Kurta
et al [28] and Lee et al [24] only reported cases of post-
operative down-staging. Kurta et al demonstrated that
among 258 patients with CT tumor size greater than 4
cm, 30 (11.6%) had a pathological size of less than 4 cm.
Among 92 patients with CT tumor size greater than 7
cm, 7 (7.6%) had a pathological size of less than 7 cm.
Lee et al demonstrated similar results. Of the 141
patients with CT tumor size between 4 cm and 7 cm,
17 (12.1%) had a pathological size less than 4 cm. Of
the 87 patients with CT tumor size greater than 7 cm, 8
(9.2%) had a pathological size of less than 7 cm.
For these patients, pre-operative counseling regarding
prognosis and management would have been based on a
clinical tumor stage that was ultimately down-staged or
up-staged based on pathological tumor size. Thus,
although the magnitude of the mean difference between
radiological and pathological tumor sizes is only 3.1
mm, there are cases where the discrepancy may impact
upon clinical management.
Authors disagree about the clinical implications of the
small but statistically significant difference between CT
and pathological tumor size. Some studies conclude that
CT adequately approximates pathological tumor size
[24,26,32,34], and that any discrepancy between the two
measurements has minimal impact on patient manage-
ment [28]. Other authors point out that overestimation
of pathological size on CT could affect selection of
patients for elective PN [29,31,33,34]. PN is the standard
o fc a r ef o rT 1 at u m o r s( ≤4 cm) [17]. Mistry et al [29]
report that 5 (5%) of their patients who were not offered
elective PN based on a CT tumor size > 40 mm, had a
pathological size ≤4 cm. Likewise, 3 patients out of 100
included in the study by Irani et al [33] were ineligible
for elective PN based on CT size > 40 mm, but had a
pathological size ≤4 cm. However, with the growing
impetus to use PN for all amenable T1 tumors [15,16],
tumor size is becoming less important for determining
patient eligibility for PN. Several authors argue that the
decision to perform elective PN should be based on
technical feasibility and patient preference rather than a
rigid tumor size cut-off [12,13,18,19,39].
The discrepancy between radiological and pathological
tumor size could have implications for the use of ablative
techniques and active surveillance for RCC. These
approaches produce no specimen for pathological assess-
ment, and so we must rely upon CT estimates of tumor
size to guide management. Decision-making under these
circumstances is aided by the small number of studies
that report tumor prognosis according to radiological
tumor size. Kanao et al [40] have recently developed a
preoperative prognostic nomogram based on clinical sta-
ging to predict survival after nephrectomy. Raj et al [41]
have also developed a preoperative nomogram to predict
the development of metastases after nephrectomy. Such
prognostic data based on clinical information can be
used as a benchmark against which the oncological out-
come of ablative techniques can be compared.
Our finding of a positive correlation between Fuhrman
grade and tumor size supports previous observations.
Table 5 Mean radiological and pathological tumor size (mm) by histological subtype
Histology N Mean CT size (SD) † Mean pathological size (SD) Mean difference (95% CI) ‡ P value
Conventional 126 60.37 (29.79) 56.56 (31.06) 3.82 (1.25 to 6.39) 0.004
Papillary 16 43.44 (22.82) 43.75 (20.12) -0.31 (-6.46 to 5.84) 0.915
Chromophobe 11 52.82 (29.12) 53.00 (38.21) -0.18 (-16.94 to 16.57) 0.981
Other 4 68.25 (19.97) 64.25 (18.95) 4.00 (-35.21 to 43.21) 0.767
† SD = standard deviation.
‡ CI = confidence interval.
Table 6 Mean radiological and pathological tumor size (mm) stratified according to type of procedure
Type of surgery N Mean CT size (SD) † Mean pathological size (SD) Mean difference (95% CI) ‡ P value
Partial nephrectomy 18 33.33 (14.21) 32.11 (13.11) 1.22 (-4.61 to 7.06) 0.664
Radical nephrectomy 139 61.55 (29.13) 58.19 (30.84) 3.37 (0.71 to 6.02) 0.013
† SD = standard deviation.
‡ CI = confidence interval.
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(N=2559) both demonstrated that larger tumors were
more likely to harbor high-grade disease, with each
1 cm increase in tumor size carrying a 25 - 32%
increased risk of high-grade disease (Fuhrman 3 or 4).
Analysis of tumors grouped according to various tumor
size breakpoints (3 cm [44], 4 cm [45], 5 cm [46]) has
also shown a higher prevalence of high-grade disease in
the larger size groups. In contrast, Klatte et al classified
tumors by an 11 cm breakpoint and found that
Fuhrman grade was similar in the two groups [47]. Our
finding that Fuhrman grade correlated with tumor stage
is also consistent with findings from other studies
[48,49]. The relationship between tumor size and Fuhr-
man grade has implications for patient counseling and
management, particularly if electing active surveillance.
Our study has several shortcomings. It is a retrospec-
tive single institution analysis. The small numbers of
papillary and chromophobe histological subtypes, and
the small number of patients treated with partial
nephrectomy were inadequately powered to detect a dif-
ference. Likewise, when categorized into 1 cm size inter-
vals, several groups had insufficient numbers to detect a
difference. There was no record of when the pre-
operative CT was performed, and so we could not
standardize the interval between imaging and surgery.
Furthermore, there was no uniform protocol for mea-
surement of CT tumor size and pathological tumor size.
There was no centralized review of measurements by a
single radiologist or pathologist.
A follow-up prospective multi-centre study with lar-
ger numbers and a uniform protocol for tumor mea-
surement should be performed to further elucidate the
relationship between CT and pathological tumor size.
There is also a need for studies examining the correla-
tion between clinical and pathological staging for
RCC. Studies that report prognosis according to radi-
ological rather than pathological tumor size would
guide us in making treatment decisions based on clini-
cal tumor size. The development and validation of
pre-operative prognostic nomograms would also aid
decision-making.
Conclusions
There was a statistically significant but small overesti-
mation (3.1 mm) of pathological size by CT overall, but
this is of uncertain clinical significance. For some
patients, the difference leads to a discrepancy between
clinical and pathological staging, which may have impli-
cations for pre-operative patient counseling regarding
prognosis and choice of treatment strategy.
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Table 7 Radiological tumor size (mm) distributed
according to Fuhrman grade
Fuhrman Grade
I II III IV N/A† Total
Radiological
tumor size (mm)
≤ 40 11 29 13 0 2 55
>40 but ≤ 70 5 37 18 1 4 65
> 70 4 14 13 5 1 37
Total 20 80 44 6 7 157
† N/A = Not available.
Table 8 Pathological T stage distributed according to
Fuhrman grade
Fuhrman Grade
I II III IV N/A† Total
Pathological T stage T1a 11 34 12 0 1 58
T1b 5 22 9 1 4 41
≥T2 4 24 23 5 2 58
Total 20 80 44 6 7 157
† N/A = Not available.
Table 9 Summary of previous studies comparing mean
radiological and mean pathological renal tumor sizes
Author Year N Mean CT
size
(mm)‡
Mean
Path size
(mm)
Mean δ
(mm)
P value
Herr [35] 1999 50 N/A N/A 6.3 0.001
Herr et al [34] 2001 87 34 27 7.4 N/A
Irani [33]† 2001 100 70.0 60.0 10.0 0.005
Yaycioglu[32] 2002 291 54 53 1.0 0.17
Schlomer [31] 2006 133 44.7 41.4 3.3 0.35
Kanofsky [30] 2006 198 51.1 49.2 1.9 N/A
Mistry [29] 2008 106 49.9 47.4 2.5 0.70
Kurta [28] 2008 521 47.9 46.9 1.0 0.02
Alicioglu [27] 2009 35 75.0 62.5 12.5 0.452
Ates [26] 2010 86 63.3 64.3 -1.0 0.342
Choi [25] 2010 175 49.8 45.5 4.3 0.152
Lee [24] 2010 467 45.6 44.9 0.7 0.399
Jeffery 2010 157 58.3 55.2 3.1 0.012
† Used median CT size and median pathological size.
‡ mm = millimetres.
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